Trials / Completed
CompletedNCT02202213
Safety and Tolerability Study of Lu AF11167 After Repeated Dosing in Patients With Schizophrenia
Interventional, Randomised, Double-blind, Placebo Controlled, Multiple-dose Study Investigating the Safety, Tolerability, PK and PD Properties of Lu AF11167 in Patients With Schizophrenia
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 47 (actual)
- Sponsor
- H. Lundbeck A/S · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and tolerability of Lu AF11167 in patients with schizophrenia following various repeated dosing regimens of Lu AF11167 (alone or as added treatment to risperidone).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | |
| DRUG | Lu AF11167 |
Timeline
- Start date
- 2013-10-01
- Primary completion
- 2015-02-01
- First posted
- 2014-07-28
- Last updated
- 2015-02-18
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02202213. Inclusion in this directory is not an endorsement.